Clinical predictor of efficacy of abiraterone acetate in metastatic castraction-resistence prostate cancer progressing after doxcetaxel treatment

碩士 === 中山醫學大學 === 醫學研究所 === 104 === BACKGROUND Abiraterone acetate (AA) had been approved in the treatment of castration resistant prostate cancer (CRPC) after docetaxel. We performed a retrospective study in patients with mCRPC patients who received AA treatment after docetaxel and identify clinica...

Full description

Bibliographic Details
Main Authors: Chin-Peng Chang, 張志鵬
Other Authors: 楊順發
Format: Others
Language:zh-TW
Published: 2016
Online Access:http://ndltd.ncl.edu.tw/handle/63pgug